Assessing early changes in plasma HER2 levels is useful for predicting therapeutic response in advanced breast cancer: A multicenter, prospective, noninterventional clinical study-Reference-Cited by-同舟云学术

Assessing early changes in plasma HER2 levels is useful for predicting therapeutic response in advanced breast cancer: A multicenter, prospective, noninterventional clinical study

Published:2022-10-24 Issue:5 Volume:12 Page:5323-5333
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Kang Yi‐Kun¹,Si Yi‐Ran¹,Ju Jie¹,Jia Zhu‐Qing²,Hu Nan‐Lin¹,Dong Hao³,Wang Xue¹,Yue Jian¹,Jiang Pei‐Di¹,Li Zhao‐Liang³,Zhang Yun‐Yun³,Wang Yan⁴,Xu Bing‐He¹,Yuan Peng¹^ORCID

Affiliation:

1. Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100021 China

2. Beijing Unicare Hospital Beijing China

3. Questgenomics Nanjing China

4. Gnomegen San Diego California USA

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5352

Reference24 articles.

1. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond

2. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

3. Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study

4. Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients

5. HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer